Aim
Cerebral small vessel disease (CSVD) is extremely common in older adults, driving mobility impairments, cognitive decline, and neuropsychiatric manifestations. It underlies half of dementia cases, a quarter of all strokes, and 85% of spontaneous intracerebral hemorrhages. Yet, no effective treatment exists, and despite established guidelines, vascular risk factors such as blood pressure remain inadequately managed in half of patients. Mobility disorders further contribute to CSVD progression by driving falls, dementia, and depression, but no personalized home-based mobility interventions are offered. To tackle this pressing challenge, we propose ENHANCE-CSVD: an innovative, primary care-based platform that integrates wearable gait and sleep sensors, remote blood pressure monitoring, digital cognitive assessment, and a cutting-edge e-health interface. Our goal is to deliver timely and cost-effective interventions to reducing reliance on specialized tertiary centers. By piloting ENHANCE-CSVD in both early and advanced CSVD populations, we aim to evaluate feasibility, effectiveness, and scalability, while informing public health policy through cost-effectiveness analyses. A multidisciplinary team will use real-life longitudinal data to streamline diagnosis, monitor progress, and adapt management plans. Using remote digital platform, we will deliver remote personalized solutions and early intervention for modifiable risk factor control, home-based cognitive and motor rehabilitation, minimizing clinic visits and expanding access to personalized care and rehabilitation for patients with CSVD. Project aligns with European Academy of Neurology and WHO strategies for preserving and improving brain health, offering a patient-centered, cost effective and scalable approach. ENHANCE-CSVD seeks to transform primary care delivery, empower patients with CSVD, and bridge the gap between cutting-edge clinical care and everyday primary care at the patients living environment.
Consortium
University of Geneva Hospitals, Clinical Neurosciences Department (CH)(Coordinator), Unit of Epidemiology at the Division of Primary Care Medicine, Geneva University Hospitals (CH), University of Geneva (CH), Leenaards Memory Center, Lausanne University Hospital and University of Lausanne (CH), CHU Angers (FR), CHU Tours (FR), Vilnius University Hospital Santaros Klinikos (LTU), Fondazione IRCCS Istituto Neurologico Carlo Besta (IT), Newel Health Srl (IT)
Swiss Principal Investigators
University of Geneva Hospitals & University of Geneva, Switzerland
Dr. Lukas Sveikata, MD, PhD, Neurologist-Scientist, Chef de Clinique, University of Geneva Hospitals & Faculty of Medicine, University of Geneva
Dr. Mayssam Nehme, MD, Unit of Epidemiology at the Division of Primary Care Medicine, Geneva University Hospitals
University of Geneva, Switzerland
Prof. Katarzyna Wac, GSEM, CUI, QoL Technologies Lab Director
MSc. Igor Matias, GSEM, CUI, QoL Technologies Lab member and Providemus.alz Leader
Study recruitment: TBC, the project starts mid 2026 the latest.